orforglipron: Clinical Trials

52 trials of orforglipron, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

32 completed, 9 recruiting, 8 active not recruiting, 3 not yet recruiting. 27 Phase 3, 21 Phase 1, 2 Phase 2, 2 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 327Completed 10, Active not recruiting 8, Recruiting 8, Not yet recruiting 1
Phase 121Completed 20, Recruiting 1
Phase 22Completed 2
Phase 42Not yet recruiting 2

Follow orforglipron: new trials by email Literature Review of orforglipron trials Research Report on orforglipron

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health Problems
Orforglipron, Placebo - Obesity, Overweight
Phase 3Not yet recruitingEli Lilly and Company1922026-12-012026-10-13
Switching to Oral Weight Management Pharmacotherapy to Prevent Weight Regain After GLP-1 Therapy Discontinuation
Phentermine Pill, Orforglipron - Obesity
Phase 4Not yet recruitingMassachusetts General Hospital602026-11-012026-07-27
PATHS-T2D: A Recall-by-Genotype Study of Physiologic and Pharmacologic Responses
Orforglipron - Diabete Type 2, Pharmacogenomic Drug Interaction
Phase 4Not yet recruitingMassachusetts General Hospital1002026-10-012026-08-31
IBI3042 Study in Healthy Participants and Overweight or Obese Participants
Orforglipron, Matching Placebo, IBI3042 - Overweight, Healthy Participants
Phase 1RecruitingInnovent Biologics (Suzhou) Co. Ltd.1042026-09-072026-09-11
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
Orforglipron, Placebo - Overweight, Prediabetic State
Phase 3RecruitingEli Lilly and Company20012026-08-262026-11-05
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting
Orforglipron - Diabetes Mellitus, Type 2, Diabetes Melletus
Phase 3RecruitingEli Lilly and Company1302026-07-152026-10-08
A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes
Orforglipron, Dulaglutide - Diabetes Mellitus, Type 2
Phase 3RecruitingEli Lilly and Company1702026-07-082026-11-05
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
Orforglipron, Placebo - Atherosclerosis Cardiovascular Disease, Chronic Kidney Disease
Phase 3RecruitingEli Lilly and Company71402025-12-012026-11-04
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
Orforglipron, Placebo - Peripheral Arterial Disease
Phase 3RecruitingEli Lilly and Company12052025-10-312026-11-04
A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight
Orforglipron, Placebo - Urinary Incontinence,Stress
Phase 3RecruitingEli Lilly and Company10002025-09-302026-11-04
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee
Orforglipron, Placebo - Osteoarthritis
Phase 3Active not recruitingEli Lilly and Company8002025-09-152026-10-08
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
Orforglipron, Placebo - Obesity, Overweight
Phase 3Active not recruitingEli Lilly and Company6002025-05-192026-04-20
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
Orforglipron, Placebo - Obesity, Overweight
Phase 3Active not recruitingEli Lilly and Company14002025-05-152026-07-31
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
Orforglipron, Placebo - Obesity, Overweight
Phase 3Active not recruitingEli Lilly and Company8002025-05-152026-07-29
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
Orforglipron, Placebo - Hypertension, Overweight or Obesity
Phase 3Active not recruitingEli Lilly and Company4872025-04-302026-05-29
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
Orforglipron, Placebo - Hypertension
Phase 3Active not recruitingEli Lilly and Company9742025-04-302026-05-29
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
Orforglipron, Placebo - Hypertension
Phase 3Active not recruitingEli Lilly and Company4872025-04-302026-05-29
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight
Orforglipron, Placebo - Obesity, Overweight
Phase 1CompletedEli Lilly and Company1202025-02-172026-02-25
A Study of Orforglipron (LY3502970) to Compare a Single Capsule and Multiple Capsules in Healthy Participants
Orforglipron - Healthy
Phase 1CompletedEli Lilly and Company862024-12-132025-06-24
A Drug-Drug Interaction Study of Orforglipron (LY3502970) With Quinidine in Healthy Participants
Orforglipron, Midazolam, Quinidine - Healthy
Phase 1CompletedEli Lilly and Company272024-12-062026-05-26

Showing 20 of 52. Sign in to see all of them.

Conditions studied

Obesity (23)  ·  Overweight (20)  ·  Diabetes Mellitus, Type 2 (15)  ·  Hypertension (3)  ·  Nutrition Disorders (2)  ·  Renal Insufficiency, Chronic (2)  ·  Arthritis (1)  ·  Behavior (1)  ·  Body Weight Changes (1)  ·  Cardiovascular Diseases (1)  ·  Endocrine System Diseases (1)  ·  Fasting (1)  ·  Feeding Behavior (1)  ·  Glucose Metabolism Disorders (1)  ·  Heart Diseases (1)

Sponsors

Eli Lilly and Company (49)  ·  Massachusetts General Hospital (2)  ·  Innovent Biologics (Suzhou) Co. Ltd. (1)

Countries

United States (37)  ·  Japan (23)  ·  China (22)  ·  Puerto Rico (17)  ·  Germany (14)  ·  Argentina (13)  ·  Czechia (12)  ·  India (12)  ·  Mexico (11)  ·  Poland (10)  ·  Spain (10)  ·  Brazil (9)  ·  South Korea (9)  ·  Greece (7)  ·  Taiwan (7)

Results publications

PMID 38402332, PMID 40481478, PMID 42577069, PMID 37351564, PMID 37369232, PMID 40544435, PMID 40960239, PMID 41275875, PMID 41765029, PMID 41994902, PMID 42120723, PMID 42251769, PMID 42259339, PMID 42383207, PMID 42607698, PMID 42750540, PMID 42815506, PMID 42830762

NIH funding

2025 (8), 2023 (2), R01DK148455 (1)